NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Palatin Technologies Inc. PTN
16 fiscal years on record · USD · FY2024 reported · SEC filings only
Growth
—
Revenue, FY2024 · full 16-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income -17.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2023 · Operating -501.0% · Net -662.3%
ROE
FY2022 · ROE -336.5%
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | · | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | 0.0 | −0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 |
| EPS, diluted $ | −32.15 | −101.16 | · | · | −0.14 | −0.10 | 0.16 | 0.12 | 0.12 | −0.33 | · | · | · | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | −336.5 | −109.8 | −51.8 | −24.8 | 56.1 | 226.6 | · | · | −160.6 | −85.0 | −168.2 | −172.3 | −93.2 | −19.2 |
| Shares out B | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.23 | 0.23 | 0.20 | 0.16 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.03 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 61 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 29 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNew Jersey
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2009